Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
Background: Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2–5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression. Nintedanib and Pirfenidone have been a breakthrough in the management of IPF. Here we evaluated the effectivenes...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier España
2019-05-01
|
| Series: | Pulmonology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531043718300990 |
| _version_ | 1811331740413722624 |
|---|---|
| author | E. Bargagli C. Piccioli E. Rosi E. Torricelli L. Turi E. Piccioli M. Pistolesi K. Ferrari L. Voltolini |
| author_facet | E. Bargagli C. Piccioli E. Rosi E. Torricelli L. Turi E. Piccioli M. Pistolesi K. Ferrari L. Voltolini |
| author_sort | E. Bargagli |
| collection | DOAJ |
| description | Background: Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2–5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression. Nintedanib and Pirfenidone have been a breakthrough in the management of IPF. Here we evaluated the effectiveness of Pirfenidone and Nintedanib in a population of IPF patients diagnosed in the last 12 months at Florence ILD Referral Centre. Methods: In the last 12 months, 82 IPF patients (66 male, mean age 78.3 ± 23.8 years) were diagnosed and started antifibrotic therapy with Pirfenidone or Nintedanib. Their clinical and functional details were analyzed retrospectively at time 0 and after 6 and 12 months of therapy. Results: The median age of the patients treated with Nintedanib was higher than that of the Pirfenidone group (p < 0.0001). The most common symptoms at disease onset were exertional dyspnoea and dry cough with no differences between the two groups (p < 0.05). All IPF patients manifested bibasal crackles at the time of diagnosis. No significant differences in FVC, FEV1, TLC and DLCO were found at time 0 or after 6 months between patients treated with Pirfenidone and Nintedanib (p > 0.05). After 1 year, lung function test parameters of patients treated with Pirfenidone had remained stable from baseline. Discussion: This study emphasizes that both antifibrotic drugs appeared to be a good therapeutic choice in terms of functional stabilization, also in older patients. Keywords: Idiopathic pulmonary fibrosis, Pirfenidone, Nintedanib |
| first_indexed | 2024-04-13T16:25:15Z |
| format | Article |
| id | doaj.art-ddde54740b9842bbb1ee8889ed6c6850 |
| institution | Directory Open Access Journal |
| issn | 2531-0437 |
| language | English |
| last_indexed | 2024-04-13T16:25:15Z |
| publishDate | 2019-05-01 |
| publisher | Elsevier España |
| record_format | Article |
| series | Pulmonology |
| spelling | doaj.art-ddde54740b9842bbb1ee8889ed6c68502022-12-22T02:39:46ZengElsevier EspañaPulmonology2531-04372019-05-01253149153Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centreE. Bargagli0C. Piccioli1E. Rosi2E. Torricelli3L. Turi4E. Piccioli5M. Pistolesi6K. Ferrari7L. Voltolini8Department of Clinical and Experimental Medicine, University Hospital Careggi, Largo Brambilla 1, 50134 Florence, Italy; Corresponding author.Department of Clinical and Experimental Medicine, University Hospital Careggi, Largo Brambilla 1, 50134 Florence, ItalyDepartment of Clinical and Experimental Medicine, University Hospital Careggi, Largo Brambilla 1, 50134 Florence, ItalyDepartment of Clinical and Experimental Medicine, University Hospital Careggi, Largo Brambilla 1, 50134 Florence, ItalyDepartment of Clinical and Experimental Medicine, University Hospital Careggi, Largo Brambilla 1, 50134 Florence, ItalyDepartment of Clinical and Experimental Medicine, University Hospital Careggi, Largo Brambilla 1, 50134 Florence, ItalyDepartment of Clinical and Experimental Medicine, University Hospital Careggi, Largo Brambilla 1, 50134 Florence, ItalyDepartment of Clinical and Experimental Medicine, University Hospital Careggi, Largo Brambilla 1, 50134 Florence, ItalyThoracic Surgery Unit, Careggi University Hospital, Largo Brambilla 1, 50134 Florence, ItalyBackground: Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2–5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression. Nintedanib and Pirfenidone have been a breakthrough in the management of IPF. Here we evaluated the effectiveness of Pirfenidone and Nintedanib in a population of IPF patients diagnosed in the last 12 months at Florence ILD Referral Centre. Methods: In the last 12 months, 82 IPF patients (66 male, mean age 78.3 ± 23.8 years) were diagnosed and started antifibrotic therapy with Pirfenidone or Nintedanib. Their clinical and functional details were analyzed retrospectively at time 0 and after 6 and 12 months of therapy. Results: The median age of the patients treated with Nintedanib was higher than that of the Pirfenidone group (p < 0.0001). The most common symptoms at disease onset were exertional dyspnoea and dry cough with no differences between the two groups (p < 0.05). All IPF patients manifested bibasal crackles at the time of diagnosis. No significant differences in FVC, FEV1, TLC and DLCO were found at time 0 or after 6 months between patients treated with Pirfenidone and Nintedanib (p > 0.05). After 1 year, lung function test parameters of patients treated with Pirfenidone had remained stable from baseline. Discussion: This study emphasizes that both antifibrotic drugs appeared to be a good therapeutic choice in terms of functional stabilization, also in older patients. Keywords: Idiopathic pulmonary fibrosis, Pirfenidone, Nintedanibhttp://www.sciencedirect.com/science/article/pii/S2531043718300990 |
| spellingShingle | E. Bargagli C. Piccioli E. Rosi E. Torricelli L. Turi E. Piccioli M. Pistolesi K. Ferrari L. Voltolini Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre Pulmonology |
| title | Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre |
| title_full | Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre |
| title_fullStr | Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre |
| title_full_unstemmed | Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre |
| title_short | Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre |
| title_sort | pirfenidone and nintedanib in idiopathic pulmonary fibrosis real life experience in an italian referral centre |
| url | http://www.sciencedirect.com/science/article/pii/S2531043718300990 |
| work_keys_str_mv | AT ebargagli pirfenidoneandnintedanibinidiopathicpulmonaryfibrosisreallifeexperienceinanitalianreferralcentre AT cpiccioli pirfenidoneandnintedanibinidiopathicpulmonaryfibrosisreallifeexperienceinanitalianreferralcentre AT erosi pirfenidoneandnintedanibinidiopathicpulmonaryfibrosisreallifeexperienceinanitalianreferralcentre AT etorricelli pirfenidoneandnintedanibinidiopathicpulmonaryfibrosisreallifeexperienceinanitalianreferralcentre AT lturi pirfenidoneandnintedanibinidiopathicpulmonaryfibrosisreallifeexperienceinanitalianreferralcentre AT epiccioli pirfenidoneandnintedanibinidiopathicpulmonaryfibrosisreallifeexperienceinanitalianreferralcentre AT mpistolesi pirfenidoneandnintedanibinidiopathicpulmonaryfibrosisreallifeexperienceinanitalianreferralcentre AT kferrari pirfenidoneandnintedanibinidiopathicpulmonaryfibrosisreallifeexperienceinanitalianreferralcentre AT lvoltolini pirfenidoneandnintedanibinidiopathicpulmonaryfibrosisreallifeexperienceinanitalianreferralcentre |